ESH Meeting Highlights 2005

 
 
 
‹‹‹ Click on the dates to see the daily articles!
 
 
 
 
June 18

Clinical Trials
Non-CV mortality increased with DBP below 70 mm Hg in Syst-Eur analysis


Dr. R. Fagard,
Belgium
 

In elderly patients (average age 70 years) a diastolic blood pressure DBP) less than 70 mm Hg was associated with increased non-cardiovascular (CV) mortality, while a DBP less than 50 mm Hg did not increase CV morbidity and mortality. These results were presented by Dr. Robert Fagard (Leuven, Belgium) at the 15th European Meeting of Hypertension in Milan, held from June 17-21, 2005.

These findings came from a further analysis of the Syst-Eur database to assess the relation between on-treatment DBP and outcomes in elderly patients with isolated systolic hypertension. The study patients had a sitting systolic blood pressure (SBP) of 160-219 mm Hg and a DBP < 95 mm Hg. The study drugs were nitrendipine with enalapril or hydroclorothiazide added as needed or placebo.

Of the 4039 active treatment patients, 490 died (248 were cardiovascular deaths) and 492 had a CV event in the 21,402 patient-years follow-up. In the placebo group, there were 129 deaths (66 CV) and 168 CV events in 5219 patient-years follow-up.

For the relative hazard ratio (RHR) calculated for 5 mm Hg categories of DBP, there was no difference in CV mortality or events whether the DBP was above or below the cut-off values. The RHR was 1.43 for a DBP less than 70 mm Hg for non-CV mortality in the active treatment group (p=0.02). There was a similar trend in the placebo group.

 
DAILY ARTICLES
ACTION subgroup analysis: Nifedipine GITS more beneficial in hypertensive patients with CAD
VALUE: Valsartan compared to amlodipine reduces new-onset diabetes in high-risk hypertensive patients
Non-CV mortality increased with DBP below 70 mm Hg in Syst-Eur analysis
Plaque number at baseline predictive of events in the ELSA study
ALLHAT: Differential effects for amlodipine compared to lisinopril
PERFECT: Perindopril improves endothelial function, may explain EUROPA results
Cardiovascular Risk Factors
 
Legal
The materials presented here were prepared by independent authors under the editorial supervision of ESHonline, and do not represent a publication of the European Society of Hypertension. These materials and the related activity are not sanctioned by the European Society of Hypertension and do not constitute an official part of that conference. These materials may discuss uses and dosages for therapeutic products that have not been approved by the nationals and internationals Laws. A qualified healthcare professional should be consulted before using any therapeutic product discussed. All readers or continuing education participants should verify all information and data before treating patients or employing any therapies described in this educational activity. Copyright © ESHonline.org.